A Multi-Center Phase I/II Open Label Study to Evaluate Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimumab. (QUAD 01: Quadruple Therapy in Melanoma)
Latest Information Update: 27 May 2024
At a glance
- Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Brain metastases; Liver metastases; Malignant melanoma
- Focus Adverse reactions
- Acronyms QUAD01
- 06 Apr 2023 Planned End Date changed from 1 Aug 2027 to 31 Aug 2023.
- 06 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 24 Mar 2022 Planned End Date changed from 1 Aug 2024 to 1 Aug 2027.